Livzon Pharmaceutical Group Inc. (LVZPF) Stock Price & Analysis
Livzon Pharmaceutical Group Inc. (LVZPF) — price $5.22 (0.00%), as of the Nov 19, 2026 trading session; market cap $4.63B.
Educational signal · not a buy or sell recommendation · How to read this
Livzon Pharmaceutical Group Inc. · LVZPF
Livzon Pharmaceutical Group Inc. is a Chinese pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products and active pharmaceutical ingredients (APIs) both domestically and internationally. The company's diverse portfolio includes products for assisted reproduction, gastrointestinal health, psychiatric and neurological conditions, and traditional Chinese medicine.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $5.22 | |
| Change on the day | 0.00% | |
| 52-week range | $3.80 – $5.22 | |
| Market capitalisation | $4.63B | — |
| Price / earnings (trailing) | 18.09 | |
| Shares traded on the day | 1 |
Price & events
Other perspectives
Council score for Livzon Pharmaceutical Group (LVZPF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 27, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Livzon Pharmaceutical Group (LVZPF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Livzon Pharmaceutical Group Inc. (LVZPF) is the company analyzed here. It employs 8,878 people and is led by Daping Liu. In Q3 FY2026 it reported revenue of CN¥2.32B and net income of CN¥356M. The market values it at $4.63B.
What do the latest results show for Livzon Pharmaceutical Group (LVZPF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of CN¥2.32B. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | CN¥2.32B | CN¥356M | CN¥0.40 (diluted) |
| Q2 FY2026 | CN¥2.12B | CN¥354M | CN¥0.40 (diluted) |
| Q1 FY2026 | CN¥2.84B | CN¥571M | CN¥0.64 (diluted) |
| Q4 FY2025 | CN¥2.86B | CN¥265M | CN¥0.30 (diluted) |
What are the financial strengths and risks for Livzon Pharmaceutical Group (LVZPF)?
Short answer · as of
The distress and quality screens read Altman Z 4.30 · Piotroski F 5. Trailing ratios: ROE 11.3% · ROA 6.7% · current ratio 1.48 · earnings yield 5.5% · free-cash-flow yield 11.0%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LVZPF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LVZPF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: LVZPF Stock
These answers are editorial: 1 of these 8 answers is drawn from the LVZPF research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is LVZPF a good stock to buy?
Stock Expert AI does not rate LVZPF buy, sell or hold. Livzon Pharmaceutical Group Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LVZPF stock price today?
The last price recorded for Livzon Pharmaceutical Group Inc. (LVZPF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for LVZPF?
Livzon Pharmaceutical Group Inc. faces several risks, including regulatory changes in China's pharmaceutical industry, increased competition from domestic and international companies, and potential intellectual property infringement. The company is also exposed to currency exchange rate fluctuations and dependence on key suppliers for APIs and raw materials. Investors should carefully consider these risks before investing in LVZPF.
What are the key factors to evaluate for LVZPF?
Evaluate LVZPF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Increased Focus on Traditional Chinese Medicine (TCM): The global market for traditional medicine is experiencing a resurgence, driven by increasing consumer interest in natural and holistic healthcare solutions. Not financial advice.
How frequently does LVZPF data refresh on this page?
LVZPF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LVZPF's recent stock price performance?
Livzon Pharmaceutical Group Inc. (LVZPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LVZPF overvalued or undervalued right now?
The trailing P/E of Livzon Pharmaceutical Group Inc. (LVZPF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LVZPF before investing?
Before investing in Livzon Pharmaceutical Group Inc. (LVZPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com